Clinical Trial Update: Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 3]

View source ↗

Summary

This update notes the completion of a long-term Phase 3 study evaluating MRA for systemic juvenile idiopathic arthritis, sponsored by Chugai Pharmaceutical.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• MRA (MRA)

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED